1. Home
  2. RDW vs ANNX Comparison

RDW vs ANNX Comparison

Compare RDW & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redwire Corporation

RDW

Redwire Corporation

HOLD

Current Price

$10.21

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$6.73

Market Cap

918.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDW
ANNX
Founded
2020
2011
Country
United States
United States
Employees
N/A
99
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
918.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RDW
ANNX
Price
$10.21
$6.73
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$12.67
$16.50
AVG Volume (30 Days)
23.0M
2.8M
Earning Date
03-09-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$296,147,000.00
N/A
Revenue This Year
$11.62
N/A
Revenue Next Year
$41.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.87
$1.29
52 Week High
$26.66
$6.83

Technical Indicators

Market Signals
Indicator
RDW
ANNX
Relative Strength Index (RSI) 56.69 71.30
Support Level $9.67 $5.85
Resistance Level $12.46 $6.83
Average True Range (ATR) 1.24 0.48
MACD 0.02 0.09
Stochastic Oscillator 55.36 100.00

Price Performance

Historical Comparison
RDW
ANNX

About RDW Redwire Corporation

Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: